Le Lézard
Classified in: Health, Business
Subject: LIC

Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY® (bexagliflozin) with TheracosBio Partnership


SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies. IPC, renowned for its commitment to supporting independent pharmacies, is set to be the first pharmaceutical wholesaler in the United States to carry and distribute BRENZAVVY.

BRENZAVVY, an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, presents a groundbreaking approach to diabetes care. As the first affordably priced, once-daily SGLT2 inhibitor, BRENZAVVY enhances access for the uninsured and simplifies care for those with insurance by eliminating insurance-company utilization management and cost-sharing hassles.

Brian Connelly, President, and CEO of TheracosBio, highlights the importance of the collaboration: "Working with IPC to make BRENZAVVY available ensures there is an affordable option on thousands of pharmacy shelves across the country. This partnership aligns with our common goal of providing pharmacists and their patients with choices that expand access."

Approximately 1 in 10 people in the United States have type 2 diabetes, with cost-related medication non-adherence reported among patients. IPC President and CEO, Marc Essensa, emphasizes the role of independent pharmacies in addressing financial stresses associated with diabetes treatment: "Making BRENZAVVY available provides a powerful way for providers to address the financial toxicity stresses that can be associated with treatment for diabetes."

BRENZAVVY, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, will be available in 20 mg oral tablets to be taken once daily. While not approved for weight or blood pressure reduction, clinical studies have shown modest decreases in both. The most common side effects include female genital mycotic infections, urinary tract infections, and changes in urination.

IPC members and customers will benefit from this exclusive arrangement, reinforcing IPC's commitment to expanding the range of cost-effective, clinically meaningful products available to independent pharmacies. For additional information about BRENZAVVY, visit IPC BRENZAVVY Page.

About Independent Pharmacy Cooperative (IPC)

Established in 1983, IPC is the nation's largest group purchasing organization owned by independent pharmacies. With a mission to maximize the success of independent pharmacists, IPC provides members with access to effective programs, products, and services designed to enhance profitability. IPC operates a secondary wholesale distribution center in Sun Prairie, WI, serving over 6,000 independent pharmacies with brand, generic, and OTC products. 

SOURCE IPC (Independent Pharmacy Cooperative)


These press releases may also interest you

at 00:05
Spirit AeroSystems [NYSE: SPR] ("Spirit") today announced it has entered into a definitive merger agreement under which The Boeing Company [NYSE: BA] ("Boeing") will acquire Spirit for $37.25 per share in Boeing common stock (subject to the collar...

at 00:01
Boeing [NYSE: BA] today announced it has entered...

30 jun 2024
Pomelo Group is proud to announce the endorsement of...

30 jun 2024
"AI in healthcare is extremely challenging. For companies, it requires not only solving scientific problems but also understanding AI technology and respecting the complexity of the healthcare industry." At the 15th Annual Meeting of the New...

30 jun 2024
On June 27, 2024, Yidu Tech Inc. (the ''Company'' or ''Yidu Tech'') (2158.HK), a leader in China's AI medical industry, announced its results for the 2024 fiscal year. During the reporting period, the Company recorded revenue of RMB 807.1 million....

30 jun 2024
Yidu Tech Inc. ("Yidu Tech" or the "Company", together with its subsidiaries and consolidated affiliated entities, the "Group", HKEX: 2158) announced its annual results for the fiscal year ended 31 March 2024 ("FY2024" or the "Reporting Period"). The...



News published on and distributed by: